Are ibogaine clinical trials available in the United States in 2026?

Yes, U.S. clinical research is active or preparing through academic and state-funded programs, especially after Texas awarded $50 million to UTHealth Houston and UTMB Health. Availability is limited and depends on enrollment criteria, location, medical screening, and IND-authorized protocols.

Is ibogaine FDA-approved for opioid addiction?

No. As of May 2026, ibogaine remains Schedule I and is not FDA-approved for opioid use disorder, alcohol use disorder, PTSD, or any other indication. Legal U.S. access is generally limited to clinical trials or rare expanded-access pathways.

When could ibogaine be FDA-approved?

The realistic approval window cited in 2026 analyses is 2030–2032. Breakthrough Therapy designation could accelerate review, but full approval still requires rigorous Phase 2b/3 or Phase 3 evidence and a safety package acceptable to the FDA.

What is the biggest safety concern in ibogaine trials?

Cardiac safety, especially QTc prolongation, is the central concern. Serious protocols use baseline ECG screening, medication review, laboratory testing, and continuous ECG telemetry during the acute 24–38 hour period.

Does ibogaine cure addiction in one treatment?

No. Observational studies suggest some patients experience months of reduced craving or abstinence, but ibogaine is not a guaranteed or permanent cure. Long-term outcomes depend on follow-up care, psychotherapy, social support, and individual medical and psychiatric factors.

How does ibogaine differ from methadone or buprenorphine?

Methadone and buprenorphine are evidence-based maintenance medications taken regularly and known to reduce overdose risk. Ibogaine is being studied as an intensive episodic intervention that may suppress withdrawal and craving without daily dosing. It is a different treatment model, not a universal replacement.

Can I legally receive ibogaine treatment outside a U.S. trial?

Not in routine U.S. medical care. Some people travel to countries where ibogaine clinics operate, such as Mexico, but those treatments are not FDA-approved and may vary widely in screening, monitoring, manufacturing quality, and follow-up.

Who should not consider ibogaine clinical trial enrollment?

People with arrhythmias, prolonged QT syndrome, serious cardiac disease, uncontrolled hypertension, severe liver disease, active psychosis, unstable bipolar disorder, or interacting medications may be excluded. Only a qualified trial team can determine eligibility.

What should I ask a trial coordinator before enrolling?

Ask whether the study is IND-authorized, what cardiac monitoring is used, what medications are excluded, how long observation lasts, what endpoints are measured, and what recovery support is provided after discharge.

Services | Ibogatrack

A practical reading path

A calmer way to examine a complicated subject.

Ibogatrack organizes information for people researching ibogaine, with attention to evidence, safety, legality and practical questions in Texas. The broader ibogaine research overview provides context for how these subjects fit together.

These offerings are informational only. They do not diagnose, recommend treatment, assess eligibility, or replace professional medical or legal advice. For the purpose and boundaries of this independent resource, see how Ibogatrack approaches its information.

What is available

Research support in plain language.

01

Trial guides

Guides separate the purpose of a clinical trial from broader claims about a substance, helping readers identify study design, participant criteria, monitoring and the questions a trial is actually trying to answer.

02

Study comparisons

Comparisons put published and registered work beside one another in a consistent frame: population, setting, intervention, outcomes and stated limitations. The aim is orientation, not a verdict.

03

Research summaries

Research summaries translate formal study language without flattening uncertainty. They note what has been measured, what remains untested, and why a finding from one setting may not carry into another.

04

Glossary and FAQs

Plain-language definitions and focused questions make terms such as protocol, adverse event, eligibility and informed consent easier to follow while keeping the original distinctions intact.

Natural-light workspace accompanying an explanation of ibogaine clinical trial evidence — Reading a trial begins with its stated question, then follows its design and limitations.

How to read a study

Evidence is more than a result line.

A clinical trial is a structured research study, not a general endorsement of a treatment. The ClinicalTrials.gov study registry explains why a record may include a protocol, eligibility criteria, outcomes and recruitment status alongside any later publication.

For people weighing Texas-specific questions, this means separating an investigation’s stated design from assumptions about availability, safety, legality or personal fit. Ibogatrack’s materials are designed to keep those categories visible.

Quiet comparison

What the resource clarifies.

Question What does the study say it is examining, and what does it not claim to answer?
Methods Who is included, what is measured, and how are safety and follow-up described?
Evidence Is the material a registry entry, a completed study, a review, or a commentary—and what limits follow from that format?
Texas context What practical and legal questions remain separate from the study record itself?

Common questions

Keeping the scope clear.

Are these medical or clinical services?

No. Ibogatrack is an independent information resource for people researching ibogaine. It is not a clinic, medical provider or licensed treatment center, and it does not provide treatment or medical advice.

What can a trial summary help me understand?

A careful summary can distinguish the study question, eligibility criteria, safety monitoring, outcomes under review and the limits of available evidence. The FDA’s clinical research overview describes clinical research as a staged process, which is useful context when reading early findings.

Does a study listing settle legal questions?

No. A listing can describe research activity, but it does not answer every state-level legal or policy question. Readers following Texas developments can consult the Texas ibogaine bill tracker alongside trial information.

Why does language matter?

Terms such as adverse event, eligibility, informed consent and outcome have specific roles in research. A shared vocabulary helps readers avoid treating a study description as an individual recommendation or guarantee.

“The useful question is often not whether a result sounds promising, but what the study was designed to show.”

A restrained next step

Start with the question behind the claim.

Use Ibogatrack’s materials to build a clearer picture of ibogaine clinical trials, then keep evidence, safety, legality and practical questions in their proper lanes.

Visit the Funded Trials Hub